期刊文献+

FBXO31对肺癌细胞增殖、克隆形成、迁移及侵袭能力的影响 被引量:1

Effect of FBXO31 on proliferation, clone formation, migration and invasion of lung cancer cells
下载PDF
导出
摘要 目的探讨FBXO31基因对肺腺癌细胞系A549增殖、克隆形成、迁移及侵袭能力的影响。方法通过脂质体转染法将FBXO31表达质粒及FBXO31 si RNA序列分别转染肺癌A549细胞,用Western blot、MTT、平板克隆、划痕和Transwell实验分别检测A549细胞中FBXO31蛋白表达、细胞增殖、克隆形成、迁移和侵袭能力。结果 Western blot显示FBXO31表达质粒转染上调A549细胞中FBXO31蛋白表达,而转染si RNA下调FBXO31蛋白表达。FBXO31基因过表达增强A549细胞增殖、克隆形成、侵袭及迁移能力,而FBXO31基因沉默抑制细胞增殖、克隆形成、侵袭及迁移能力(P<0.01)。结论 FBXO31基因可促进肺癌细胞增殖、克隆形成、迁移及侵袭能力。 Objective To investigate the effect of FBXO31 on proliferation, clone formation, migration and invasion of lung cancer cells. Methods FBXO31 expressing plasmids and siRNAs were respectively transfected into A549 cells using lipofection. FBXO31 expression, proliferation, colony formation, migration, and invasion ofA549 cells were determined by Western blot, MTT, plate clone formation, wound scratch and Transwell assays, respectively. Results Western blot showed that FBXO31 plasmid transfection upregulated FBXO31 expression, while FBXO31 siRNAs downregulated FBXO31 expression. FBXO31 gene overexpression enhanced the proliferation, colony formation, migration and invasion ofA549 cells, but FBXO31 gene silence inhibited these capacities (P〈0.01). Conlusion FBXO31 gene can promote the proliferation, colony formation, migration and invasion ofA549 cells.
出处 《广东医学院学报》 2016年第4期351-356,共6页 Journal of Guangdong Medical College
基金 广东省自然科学基金(No.S2012040006537) 广东省卫生厅医学科研基金(No.B2014309) 广东医学院医学科研基金博士启动项目(No.XB1224) 广东医学院附属医院博士启动项目(No.BK201202)
关键词 FBXO31 肺癌 增殖 侵袭 FBXO31 lung cancer proliferation invasion
  • 相关文献

参考文献1

二级参考文献8

  • 1National Lung Screening Trial Research Team, Aberle DR, AdamsAM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365: 395-409.
  • 2Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366: 1527-1537.
  • 3Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol, 2006, 1: 847-855.
  • 4Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353: 123-132.
  • 5Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase II1 trial. Lancet, 2008, 372: 1809-1818.
  • 6Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenoearcinoma. N Engl J Med, 2009, 361 : 947-957.
  • 7Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell, 2009, 139: 871- 890.
  • 8Subramanian G, Schwarz RE, Higgins L, et al. Targeting endogenous transforming growth factor-β receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotypel. Cancer Res, 2004, 64: 5200-5211.

共引文献6

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部